Abbott Laboratories recieved a FDA warning letter after failing to investigate and resolve risks related to its implanted heart devices.
In a warning letter, the FDA critiziced Abbott Laboratories for failing to resolve issues related to its cardiovascular devices.
Battery and cybersecurity problems with the heart devices seemed to be a dominant issue.
Concerns about the safety of several implantable defibrillators and its Merlin@home monitor, which allows doctors to care remotely for patients with cardiac devices.
In February, we covered complicatipons with the HeartMate PHP catheter. During procedures to unclog blood vessels, the HeartMate PHP is inserted in the heart to keep blood flowing. The device is used inside the heart with no need for open-chest surgery.
The most recent investigation showed that lithium batteries in the devices weredraining and that the company had “underestimated the occurrence of the hazardous situation.”
As recently as September, the device received praised from the medical community.
Now, the Lab is putting an end to the commercially successful blood pumps use in the United States and Europe after several malfunctions and a patient death.
In late 2016, there were reports that the Merlin@home transmitter used in monitoring certain (then St. Jude Medical) implant devices could be hacked. These hacks could lead to deadly consequences for the patient.
The devices in question are several cardiovascular devices acquired in Abbot’s $25 billion purchase of St. Jude Medical.
In an email to the FDA, the company said that it was looking into the matter.
The FDA has publicly noted that Abbott had failed to provide evidence that the actions had actually been implemented.
Paxil suicide risk was disclosed, according to GlaxoSmithKline.
According to the GlaxoSmithKline court filing, the FDA refused four requests to change labels on the antidepressant Paxil to update a warning label to reflect that “there was a statistically significant increase in the frequency of suicidal behavior in patients treated with paroxetine.”
As far back as 2006 the antidepressant and its controlled-release version, Paxil CR, added a warning about suicide risk in young adults. Facts such as this are of increasing importance as GlaxoSmithKline fights a complicated lawsuit.
The suit was brought on by the widow of Stewart Dolin, a Paxil user who at the time of his suicide was taking a generic version of the drug. The $12 million suit alleges that GlaxoSmithKline was negligent in not updating the warning label to demonstrate the risk for suicide while using.
The claim insists that the labeling did not provide enough information about the risk of suicide, which as a result led to the Chicago lawyer jumping in front of a train just 6 days into using a generic form of Paxil.
Dolin’s widow’s complaint notes that certain dangerous side-effects were listed on the label, but the labeling did not properly represent the risk posed. In fact, labeling only highlighted an increase in suicidal thoughts for users under the age of 24.
She further claims that doctors were not informed about the suicide risks in adults associated with the drugs, and had that information been clear, Mr. Dolin would have been prescribed the drug.
As the trial drags on in Illinois, GlaxoSmithKline a federal jury Wednesday that the U.S. Food and Drug Administration claims that the FDA rejected a label change to Paxil four times. The updated label would have addressed the increased risk of suicide on adult patients.
If you or someone that you love has been effected by the use of Paxil, connect with an attorney at Medical Claim Legal. You could be entitled to financial compensation, find out now.
The FDA has linked BIA-ALCL deaths to a breast implants.
In 1997, The World Health Organization first made the link between the rare cancer and breast implants, breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) occurs in a capsule of tissue that develops around the implant. The cancer typically surfaces around ten-year following the breast implantation.
The FDA was quoted this week saying that “…the available information suggests women with breast implants have a very low, but increased risk of ALCL compared to women who do not have breast implants.”
Women that have both silicone and saline-filled breast implants have been affected by ALCL.
The FDA says, it has received 359 reports of the lymphoma.
One recent study determined that 3.3 out of every 100,000 women with textured breast implants will develop BIA-ALCL. The textured breast implant variety seem to have the highest occurence of the cancer diagnosis according to FDA and the Australian government.
If you or a loved one has been diagnosed with BIA-ALCL, you may be entitled to compensation due to your pain and suffering. Let the Medical Claim Legal team help you through the process.
Lupron was injected in thousands of women in an effort to inhibit puberty or increase height.
More than 10,000 adverse event reports have been filed with the FDA based on the experiences of women who’ve taken Lupron. The reports describe a variety of symptoms experienced by those who took the drug to grow taller or delay puberty.
Lupron, currently manufactured by AbbVie, is an injection designed to reduce testosterone in men or estrogen in women. The drug is also approved for use by men with prostate cancer.
The experiences of the women that used the drugs are varied but complex. Many women reported experiencing symptoms and conditions linked to older, even elderly people. According to the FDA reports:
A 20-year-old was diagnosed with osteopenia, a thinning of the bones. A 26-year-old in Massachusetts needed a total hip replacement. One 25-year-old woman from Pennsylvania has osteoporosis and a cracked spine. In Wisconsin, another woman in her 20’s has chronic pain and degenerative disc disease.
Other women described depression and anxiety.
Additionally, the FDA is reviewing deadly seizures caused by the use of Lupron and similar drugs.
The drug has had success in the marketplace. In 2015, the drug-maker reportedly brought in $826 million in sales.